Core Viewpoint - The announcement highlights that Guangxi Wuzhou Zhongheng Group Co., Ltd.'s subsidiary, Chongqing Laimei Pharmaceutical Co., Ltd., has received drug registration certificates for two medications, Nicorandil Tablets and Ketorolac Tromethamine Injection, which will enhance the company's product line and market presence [1][3]. Group 1: Drug Registration Details - Chongqing Laimei Pharmaceutical has obtained registration for Nicorandil Tablets (5mg) and Ketorolac Tromethamine Injection (1ml:30mg) from the National Medical Products Administration [1][5]. - Nicorandil Tablets are indicated for the treatment of angina pectoris, originally developed by Daiichi Sankyo Co., Ltd. and launched in Japan in 1983, with sales in China starting in 2006 [1][2]. - Sales projections for Nicorandil Tablets in Chinese hospitals from 2022 to 2024 are estimated at CNY 676 million, CNY 789 million, and CNY 873 million, respectively [1][2]. Group 2: Market and Financial Impact - Ketorolac Tromethamine Injection is used for the short-term treatment of moderate to severe postoperative pain, developed by Roche and approved in China in 2005 [2]. - Sales projections for Ketorolac Tromethamine Injection in Chinese hospitals from 2022 to 2024 are estimated at CNY 2.643 billion, CNY 1.892 billion, and CNY 898 million, respectively [2]. - The total R&D investment for Nicorandil Tablets and Ketorolac Tromethamine Injection by Laimei Pharmaceutical is CNY 5.3879 million and CNY 4.7431 million, respectively [2].